Last Updated : July 22, 2025
Current state: Open
Feedback period: July 22, 2025, to September 15, 2025
Clinician input is vital to the work we do at Canada’s Drug Agency (CDA-AMC). The valuable insights and perspectives that clinician groups provide through their input to our drug reimbursement review process help to inform our assessments of the clinical and economic evidence and the deliberations of our expert committees.
We are inviting interested clinician groups and individual clinicians to provide their insights to inform how we evolve clinician group input submissions to the drug reimbursement reviews process.
We are seeking feedback on how to best evolve clinician group input to better:
We are inviting representatives from clinician groups and individual clinicians to contribute feedback and ideas in 1 of 2 ways:
We encourage participants to review the Clinician Group Input – Background Reading in preparation for engagement activities.
During small group discussions, our team will present an overview of how clinician perspectives support the drug reimbursement review process, including expert committee deliberations. We will also share our goals to enhance this process and facilitate a discussion where participants can share their perspectives and suggestions.
Use the Small Group Registration Form to register and submit your availability for 1 of the 5 sessions:
To ensure we can engage with a diverse range of perspectives, we kindly ask that each clinician group designate only 1 representative to attend. This will help us include as many perspectives as possible in our discussions.
Please fill out the Feedback on Evolving Clinician Group Input Form to provide written comments. Feedback must be received by 5:00 p.m. ET on September 15, 2025. For feedback to be considered, individuals and organizations must be identified by name. One response per organization will be considered.
If you are interested in being involved in this process, but unable to attend a small group discussion session or provide written feedback, please contact us at [email protected] to discuss alternate ways to share your insights.